Home Antibody All anti-F13A1 antibodies
Anti-F13A1 GAT Antibody Polyclonal
Generated by Genomic Immunization
Also for F13A1 (NM_000129)
|DNA immunization. This antibody is specific for the C Terminus Region of the target protein.|
|20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0|
|The fragment used for DNA immunization was expressed in E.coli and the purified protein fragment was used for affinity purification of the antibody.
|This antibody was generated by SDIX's Genomic Antibody Technology ® (GAT). Learn about GAT
|Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1)|
Entrez Gene 2162 Human
|Factor XIII is a beta globulin found in plasma and is composed of two subunits. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Factor XIII A is the catalytic subunit and is a dimmer of molecular weight 160kDa. The B subunits do not have enzymatic activity and may serve as a plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon activation by the cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIII A, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine cross linking between fibrin molecules, thus stabilizing the fibrin clot. It also cross links alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion. Factor XIII A is a dermal dendrocyte marker and shows variable reaction with these types of tumors. It can be used for histiocytic phenotyping and has been reported to mark capillary hemangiomas and tumors of the central nervous system.|
|Secreted ProteinDruggable Genome Complement and coagulation cascades|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.